<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347620">
  <stage>Registered</stage>
  <submitdate>23/10/2011</submitdate>
  <approvaldate>14/11/2011</approvaldate>
  <actrnumber>ACTRN12611001180909</actrnumber>
  <trial_identification>
    <studytitle>Assessment of effect of granulocyte colony stimulating factor (G-CSF) on immune response to vaccination against hepatitis B in patients awaiting liver transplantation.</studytitle>
    <scientifictitle>Is the titer of Anti HBS Ab in cirrhotic patients receiving double dose HBV vaccine and simultaneous granulocyte-colony stimulating factor (G-CSF) higher compared to cirrhotic patients receiving only double dose HBV vaccine?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>N/A</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Immunity against hepatitis B virus</healthcondition>
    <healthcondition>cirrhosis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intramuscular injection of double dose of HBV vaccine (40 micro gr) and simultaneous injection of Granolocyte monocyte colony stimulating factor (GM-CSF) (300 micro gr). 3 doses of HBV vaccine at months 0,1 and 2 will be injected. GM-CSF will be administered after each injection of HBV vaccine.</interventions>
    <comparator>Intramuscular injection of double dose of HBV vaccine without GM-CSF</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>antibody against hepatitis B surface antigen (anti-HBS antibody) with a titer of 10IU/L or more after blood analysis, This was measured by blood sample analysis. The titer of anti HBS antibody in blood samples will be examined</outcome>
      <timepoint>1 month after first dose of vaccine; and again 1 month after the last dose of vaccine ((the end of 3rd month )</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>None</outcome>
      <timepoint>None</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Cirrhotic patients between 20 and 65 years on waiting list for liver transplantation</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Previous history of viral hepatitis (HBS POSITIVE OR anti HBC Ab positive 2. HIV patients 3. Those patients who has history of vaccination 4. Patients with hepatocellular carcinoma 5. Patients with congestive heart failure (class III and IV) 6. Patients with serum creatinine &gt;1.5 mg/dL 7. Patients with hypersensitivity to GM-CSF
8. Using immunosuppresive agents like azathioporine, tacrolimus.....</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Kamran Bagheri Lankarani</primarysponsorname>
    <primarysponsoraddress>Health policy research center,5th floor, Shiraz medical school, Zand Ave, Shiraz, Fars province, Iran. P.C: 71345-1877</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Shiraz University of medical science-</fundingname>
      <fundingaddress>7th floor, Deputy of research and technology, Shiraz University of medical sciences, Zand Ave, Shiraz, Fars province, Iran, P.C:71345-1845</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Shiraz University of medical science-</sponsorname>
      <sponsoraddress>7th floor, Deputy of research and technology, Shiraz University of medical sciences, Zand Ave, Shiraz, Fars province, Iran, P.C:71345-1845</sponsoraddress>
      <sponsorcountry>Iran, Islamic Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will be conducted to evaluate the effect of GM-CSF in titer of HBV antibody in patients with cirrhosis</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Local ethical committe of Shiraz University of medical sciences</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Kamran B Lankarani</name>
      <address>Health policy research center, 5th floor, Shiraz University of medical science, Zand Ave, Shiraz, Fars, Iran. P.C: 71345-1877</address>
      <phone>+ 98 711 2309615</phone>
      <fax />
      <email>lankaran@sums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ahad Eshraghian</name>
      <address>Internal medicine department, Namazi Hospital, Shiraz, Fars, Iran P.C 71345-1744</address>
      <phone>+98 9177311442</phone>
      <fax />
      <email>eshraghiana@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>